All Stories

  1. Clinical Burden and Healthcare Resource Use of Asthma in Children in the UK

    Article • Journal of Asthma and Allergy, February 2025, Taylor & Francis

    Asif Khan

  2. Epidemiology of Childhood Asthma in the UK

    Article • Journal of Asthma and Allergy, November 2024, Taylor & Francis

    Asif Khan

  3. Dupilumab efficacy across serum IgE and blood eosinophil levels in chronic rhinosinusitis with nasal polyposis

    Article • Allergy, June 2024, Wiley

    Asif Khan

  4. Dupilumab Reduces Asthma Disease Burden and Recurrent SCS Use in Patients with CRSwNP and Coexisting Asthma

    Article • Journal of Asthma and Allergy, January 2024, Taylor & Francis

    Asif Khan

  5. Impact of Dupilumab on Sinonasal Symptoms and Outcomes in Severe Chronic Rhinosinusitis With Nasal Polyps

    Article • Otolaryngology, December 2023, Wiley

    Asif Khan

  6. Dupilumab efficacy in high sleep disturbance management among patients with type 2 asthma

    Article • Respiratory Medicine, November 2023, Elsevier

    Asif Khan

  7. Dupilumab leads to better-controlled asthma and quality of life in children: the VOYAGE study

    Article • European Respiratory Journal, September 2023, European Respiratory Society (ERS)

    Asif Khan

  8. Oral corticosteroid (OCS) burden and healthcare resource utilization (HCRU) in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) who did or did not undergo functional endoscopic sinonasal surgery (FESS) in US real-world practice

    Article • September 2023, European Respiratory Society (ERS)

    Asif Khan

  9. The relationship of sinus opacification, olfaction and dupilumab efficacy in patients with CRSwNP

    Article • Rhinology Journal, July 2023, Rhinology

    Asif Khan

  10. Dupilumab Improves Outcomes in Patients with Chronic Rhinosinusitis with Nasal Polyps and Coexisting Asthma Irrespective of Baseline Asthma Characteristics

    Article • Journal of Asthma and Allergy, April 2023, Taylor & Francis

    Asif Khan

  11. Health-Related Quality of Life Impairment Among Patients with Severe Chronic Rhinosinusitis with Nasal Polyps in the SINUS-24 Trial

    Article • Journal of Asthma and Allergy, March 2023, Taylor & Francis

    Professor Carl Philpott, Asif Khan

  12. Content Validation of Patient-Reported Sleep Measures and Development of a Conceptual Model of Sleep Disturbance in Patients with Moderate-to-Severe, Uncontrolled Asthma

    Article • Patient Related Outcome Measures, March 2023, Taylor & Francis

    Asif Khan

  13. Prevalence and Severity Distribution of Type 2 Inflammation-Related Comorbidities Among Patients with Asthma, Chronic Rhinosinusitis with Nasal Polyps, and Atopic Dermatitis

    Article • Lung, February 2023, Springer Science + Business Media

    Asif Khan

  14. Dupilumab provides early and durable improvement of symptoms in patients with chronic rhinosinusitis with nasal polyps

    Article • Clinical & Translational Immunology, January 2023, Wiley

    Asif Khan

  15. Immunolab: Combining targeted real-world data with advanced analytics to generate evidence at scale in immunology

    Article • Frontiers in Allergy, November 2022, Frontiers

    Asif Khan

  16. Impact of Baseline Lung Function on Future Exacerbations in Patients with Moderate-to-Severe Asthma

    Article • Journal of Asthma and Allergy, November 2022, Taylor & Francis

    Asif Khan

  17. Impact of exacerbations on lung function, resource utilization, and productivity: results from an observational, prospective study in adults with uncontrolled asthma

    Article • Journal of Asthma, October 2022, Taylor & Francis

    Asif Khan

  18. Impact of dupilumab on SNOT-22 sleep and function scores in CRSwNP

    Article • The Journal of Allergy and Clinical Immunology In Practice, September 2022, Elsevier

    Asif Khan

  19. Efficacy and Safety of Dupilumab Versus Omalizumab in Chronic Rhinosinusitis With Nasal Polyps and Asthma: EVEREST Trial Design

    Article • American Journal of Rhinology and Allergy, July 2022, SAGE Publications

    Asif Khan

  20. Improvement in patient‐reported “taste” and association with smell in dupilumab‐treated patients with severe chronic rhinosinusitis with nasal polyps from the SINUS ‐24 and SINUS ‐52...

    Article • Clinical & Experimental Allergy, July 2022, Wiley

    Asif Khan

  21. Improvement in Health-Related Quality of Life with Dupilumab in Patients with Moderate-to-Severe Asthma with Comorbid Chronic Rhinosinusitis with/without Nasal Polyps: An Analysis of the QUEST Study

    Article • Journal of Asthma and Allergy, June 2022, Taylor & Francis

    Asif Khan

  22. Dupilumab Demonstrates Rapid Onset of Response Across Three Type 2 Inflammatory Diseases

    Article • The Journal of Allergy and Clinical Immunology In Practice, June 2022, Elsevier

    Asif Khan

  23. Content validity of a newly developed observer-reported measure for pediatric asthma in children aged 2–5 years

    Article • Journal of Patient-Reported Outcomes, May 2022, Springer Science + Business Media

    Asif Khan

  24. Rapid and Continuing Improvements in Nasal Symptoms with Dupilumab in Patients with Severe CRSwNP

    Article • Journal of Asthma and Allergy, May 2022, Taylor & Francis

    Asif Khan

  25. Asthma Daytime Symptom Diary (ADSD) and Asthma Nighttime Symptom Diary (ANSD): Measurement Properties of Novel Patient-Reported Symptom Measures

    Article • The Journal of Allergy and Clinical Immunology In Practice, May 2022, Elsevier

    Asif Khan

  26. Olfactory Outcomes With Dupilumab in Chronic Rhinosinusitis With Nasal Polyps

    Article • The Journal of Allergy and Clinical Immunology In Practice, April 2022, Elsevier

    Asif Khan

  27. Dupilumab Improves Asthma Control, and Allergic Rhinitis-Related Health-Related Quality of Life in Children With Uncontrolled Persistent Asthma With Comorbid Allergic Rhinitis

    Article • Journal of Allergy and Clinical Immunology, February 2022, Elsevier

    Asif Khan

  28. Dupilumab achieves durable reduction in severity of symptoms rated most important by patients with chronic rhinosinusitis with nasal polyps

    Article • Journal of Allergy and Clinical Immunology, February 2022, Elsevier

    Asif Khan

  29. Dupilumab improves objective, subjective, and health-related quality of life outcomes in chronic rhinosinusitis with nasal polyps (CRSwNP), regardless of BMI ≥30 kg/m2 or weight ≥90 kg: post-hoc analysis of the SINUS-24 and SINUS-52 studies

    Article • Journal of Allergy and Clinical Immunology, February 2022, Elsevier

    Asif Khan

  30. Dupilumab leads to reduction of anosmia in patients with severe chronic rhinosinusitis with nasal polyps

    Article • Journal of Allergy and Clinical Immunology, February 2022, Elsevier

    Asif Khan

  31. Dupilumab reduces asthma disease burden and recurrent SCS use in patients with CRSwNP and coexisting asthma

    Article • Journal of Allergy and Clinical Immunology, February 2022, Elsevier

    Asif Khan

  32. EValuating trEatment RESponses of dupilumab versus omalizumab in Type 2 patients: the EVEREST Trial

    Article • Journal of Allergy and Clinical Immunology, February 2022, Elsevier

    Asif Khan

  33. Symptom Free Days In Patients With Severe Chronic Rhinosinusitis with Nasal Polyps Treated with Dupilumab

    Article • Journal of Allergy and Clinical Immunology, February 2022, Elsevier

    Asif Khan

  34. Dupilumab improves health related quality of life: Results from the phase 3 SINUS studies

    Article • Allergy, February 2022, Wiley

    Asif Khan

  35. Dupilumab efficacy and biomarkers in chronic rhinosinusitis with nasal polyps: Association between dupilumab treatment effect on nasal polyp score and biomarkers of type 2 inflammation in patients with chronic rhinosinusitis with nasal polyps in the ph...

    Article • International Forum of Allergy & Rhinology, January 2022, Wiley

    Asif Khan

  36. Rapid and sustained effects of dupilumab in severe chronic rhinosinusitis with nasal polyps

    Article • International Forum of Allergy & Rhinology, January 2022, Wiley

    Asif Khan

  37. Response to the correspondence: “Non-optimal methodology questions indirect treatment comparison of dupilumab vs other biologics in severe asthma”

    Article • Respiratory Medicine, January 2022, Elsevier

    Asif Khan

  38. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study

    Article • The Lancet Respiratory Medicine, January 2022, Elsevier

    Asif Khan

  39. Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma

    Article • Respiratory Medicine, January 2022, Elsevier

    Asif Khan

  40. Response to comment on: Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma (Respir. Med. 2020)

    Article • Respiratory Medicine, January 2022, Elsevier

    Asif Khan

  41. Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, December 2021, New England Journal of Medicine (NEJM/MMS)

    Asif Khan

  42. Estimating Clinically Meaningful Change of Efficacy Outcomes in Inadequately Controlled Chronic Rhinosinusitis with Nasal Polyposis

    Article • The Laryngoscope, December 2021, Wiley

    Asif Khan

  43. Dupilumab in CRSwNP : Responder Analysis Using Clinically Meaningful Efficacy Outcome Thresholds

    Article • The Laryngoscope, November 2021, Wiley

    Asif Khan

  44. Data Mining of Free-Text Responses: An Innovative Approach to Analyzing Patient Perspectives on Treatment for Chronic Rhinosinusitis with Nasal Polyps in a Phase IIa Proof-of-Concept Study for Dupilumab

    Article • Patient Preference and Adherence, November 2021, Taylor & Francis

    Asif Khan

  45. P184 IMPACT OF DUPILUMAB ON SLEEP/FUNCTION SCORES IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS

    Article • Annals of Allergy Asthma & Immunology, November 2021, Elsevier

    Asif Khan

  46. SNOT-22 items and association with objective measures in dupilumab-treated patients with severe chronic rhinosinusitis with nasal polyps from SINUS-24 and SINUS-52 trials

    Article • September 2021, European Respiratory Society (ERS)

    Asif Khan

  47. Effect of dupilumab on patient-reported sleep outcomes in patients with severe asthma

    Article • September 2021, European Respiratory Society (ERS)

    Asif Khan

  48. Dupilumab improves asthma control and quality of life in children with uncontrolled persistent asthma

    Article • September 2021, European Respiratory Society (ERS)

    Asif Khan

  49. Effect of dupilumab on improving physical activity in patients with severe asthma

    Article • September 2021, European Respiratory Society (ERS)

    Asif Khan

  50. Association Between a Type 2 Inflammatory Disease Burden Score and Outcomes Among Patients with Asthma

    Article • Journal of Asthma and Allergy, September 2021, Taylor & Francis

    Asif Khan

  51. Development of Sinonasal Outcome Test (SNOT‐22) Domains in Chronic Rhinosinusitis With Nasal Polyps

    Article • The Laryngoscope, August 2021, Wiley

    Asif Khan

  52. Association Between Dupilumab Effect on Nasal Polyp Score and Biomarkers of Type 2 Inflammation in Patients with Chronic Rhinosinusitis with Nasal Polyps in the Phase 3 SINUS-24 and SINUS-52 Trials

    Article • May 2021, American Thoracic Society

    Asif Khan

  53. Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma

    Article • Annals of Allergy Asthma & Immunology, May 2021, Elsevier

    Asif Khan

  54. Dupilumab reduces systemic corticosteroid use and sinonasal surgery rate in CRSwNP

    Article • Rhinology Journal, April 2021, Rhinology

    Asif Khan

  55. Reducing Fungal Exposure Critical for Treating Rhinosinusitis with or without Polyps [Response to Letter]

    Article • Journal of Asthma and Allergy, April 2021, Taylor & Francis

    Asif Khan

  56. Burden of Disease in Chronic Rhinosinusitis with Nasal Polyps

    Article • Journal of Asthma and Allergy, February 2021, Taylor & Francis

    Asif Khan

  57. Health-Related Quality of Life Impairment Among Patients With Severe Chronic Rhinosinusitis With Nasal Polyps in the SINUS-24 Trial

    Article • Journal of Allergy and Clinical Immunology, February 2021, Elsevier

    Asif Khan, Professor Carl Philpott

  58. Efficacy of dupilumab on clinical outcomes in patients with asthma and perennial allergic rhinitis

    Article • Annals of Allergy Asthma & Immunology, November 2020, Elsevier

    Asif Khan

  59. ASSOCIATION BETWEEN ASTHMA SEVERITY, QUALITY OF LIFE, AND PRODUCTIVITY IN FRANCE, GERMANY, ITALY, SPAIN, AND THE UNITED KINGDOM

    Article • CHEST Journal, October 2020, Elsevier

    Asif Khan

  60. DUPILUMAB IMPROVES PATIENT-REPORTED BREATHING IN ORAL CORTICOSTEROID-DEPENDENT SEVERE ASTHMA

    Article • CHEST Journal, October 2020, Elsevier

    Asif Khan

  61. DUPILUMAB REDUCES SEVERE OUTPATIENT ASTHMA EXACERBATIONS, CUMULATIVE DOSE, AND TOTAL NUMBER OF DAYS OF SYSTEMIC CORTICOSTEROID USE AMONG PATIENTS WITH MODERATE-TO-SEVERE TYPE-2 ASTHMA

    Article • CHEST Journal, October 2020, Elsevier

    Asif Khan

  62. PREVALENCE OF ASTHMA IN FRANCE, GERMANY, ITALY, SPAIN, AND THE UNITED KINGDOM, BASED ON THE 2018 EUROPEAN NATIONAL HEALTH AND WELLNESS SURVEY

    Article • CHEST Journal, October 2020, Elsevier

    Asif Khan

  63. Type 2 inflammation-related comorbidities among patients with asthma, chronic rhinosinusitis with nasal polyps, and atopic dermatitis

    Article • September 2020, European Respiratory Society (ERS)

    Asif Khan

  64. Effect of Dupilumab on patient-reported breathing and rescue medication use

    Article • September 2020, European Respiratory Society (ERS)

    Asif Khan

  65. Dupilumab Improves Asthma Control as Assessed by Total and Individual Item Scores of the 6-Item Asthma Control Questionnaire in Patients with Severe Chronic Rhinosinusitis with Nasal Polyps and Comorbid Asthma: Pooled Results from the SINUS-24 and SINU...

    Article • May 2020, American Thoracic Society

    Asif Khan

  66. Dupilumab Efficacy in Uncontrolled, Moderate-to-Severe Asthma with Self-Reported Chronic Rhinosinusitis

    Article • The Journal of Allergy and Clinical Immunology In Practice, February 2020, Elsevier

    Asif Khan

  67. Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic Asthma

    Article • The Journal of Allergy and Clinical Immunology In Practice, February 2020, Elsevier

    Asif Khan

  68. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials

    Article • The Lancet, November 2019, Elsevier

    Professor Carl Philpott, Asif Khan

  69. Dupilumab improves health‐related quality of life in patients with chronic rhinosinusitis with nasal polyposis

    Article • Allergy, October 2019, Wiley

    Asif Khan

  70. Dupilumab reduces opacification across all sinuses and related symptoms in patients with CRSwNP

    Article • Rhinology Journal, October 2019, Rhinology

    Asif Khan

  71. Dupilumab improves nasal polyp burden and asthma control in patients with CRSwNP and AERD

    Article • The Journal of Allergy and Clinical Immunology In Practice, September 2019, Elsevier

    Asif Khan

  72. Dupilumab improves patient-reported outcomes in patients with chronic rhinosinusitis with nasal polyps and comorbid asthma

    Article • The Journal of Allergy and Clinical Immunology In Practice, September 2019, Elsevier

    Asif Khan

  73. Dupilumab improves asthma outcomes irrespective of frequency of previous asthma exacerbation history

    Article • Annals of Allergy Asthma & Immunology, August 2019, Elsevier

    Asif Khan

  74. Dupilumab Improved Asthma Control and Health-Related Quality of Life in Patients with Oral-Corticosteroid-Dependent Severe Asthma in the Phase 3 LIBERTY ASTHMA VENTURE Study

    Article • May 2019, American Thoracic Society

    Asif Khan

  75. Dupilumab Improved Morning and Evening Daily Asthma Symptoms in Patients with Oral-Corticosteroid-Dependent Severe Asthma in the Phase 3 LIBERTY ASTHMA VENTURE Study

    Article • May 2019, American Thoracic Society

    Asif Khan

  76. Dupilumab Improved Asthma Control in Patients With Uncontrolled, Moderate-to-Severe Asthma, Regardless of Exacerbations in the Previous Year

    Article • Pneumologie, February 2019, Thieme Publishing Group

    Asif Khan

  77. Cost burden and resource utilization in patients with chronic rhinosinusitis and nasal polyps

    Article • The Laryngoscope, February 2019, Wiley

    Asif Khan

  78. The Global Allergy and Asthma European Network (GALEN rhinosinusitis cohort: a large European cross-sectional study of chronic rhinosinusitis patients with and without nasal polyps

    Article • Rhinology Journal, February 2019, Rhinology

    Asif Khan

  79. The GALEN rhinosinusitis cohort: chronic rhinosinusitis with nasal polyps affects health-related quality of life

    Article • Rhinology Journal, January 2019, Rhinology

    Asif Khan

  80. DUPILUMAB IMPROVES ASTHMA CONTROL IN PATIENTS WITH UNCONTROLLED, MODERATE-TO-SEVERE ASTHMA, REGARDLESS OF EXACERBATION HISTORY

    Article • Annals of Allergy Asthma & Immunology, November 2018, Elsevier

    Asif Khan

  81. IMPACT OF CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS ON QUALITY OF LIFE BY SINO-NASAL SURGERY HISTORY

    Article • Annals of Allergy Asthma & Immunology, November 2018, Elsevier

    Asif Khan

  82. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, June 2018, New England Journal of Medicine (NEJM/MMS)

    Asif Khan

  83. Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, June 2018, New England Journal of Medicine (NEJM/MMS)

    Asif Khan

  84. Dupilumab Improves Sense of Smell and Reduces Anosmia Among Patients with Nasal Polyposis and Chronic Sinusitis: Results from a Phase 2a Trial

    Article • Journal of Allergy and Clinical Immunology, February 2017, Elsevier

    Asif Khan